A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...
We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.